The clinical link among diabetes, obesity, and thyroid dysfunction is of interest. Hence, medical records of 601 patients with diabetes, obesity, and thyroid dysfunctions at the Abha Specialist Center and Military Diabetic Endocrine Center we used in this analysis. Approximately 28% of diabetic patients had thyroid dysfunction, and 12.4% were vitamin D deficient. The patients with thyroid dysfunction had significantly elevated triglyceride levels compared to the patients without thyroid dysfunction (173.6 vs. 128. p=0.009). Vitamin D deficient obese patients were significantly younger (33.99±10.69 vs. 43.68±14.42; p<0.001) and had significantly lower levels of HbA1c (5.73±1.16 vs. 6.83±2.08; p=0.014) and lower systolic BP (120.26±11.75 vs. 124.58±13.63; p=0.049) than non-vitamin D deficient obese patients. Vitamin D deficient thyroid patients had significantly lower diastolic BP (71.4±9.9 vs. 74.9±9.7; p=0.040) and higher HbA1c (8.7±3.6 vs. 6.4±1.7; p=0.003) in comparison to non-vitamin D deficient thyroid patients. Hence, analysis of metabolic disorders in these patients will help combat complications in these cases.

Although acromegaly has been associated with increased mortality rates, evidence shows that the application of the recent treatment modalities has reduced the risk of death in these patients, being comparable with the general population. As a result of the changing trends regarding mortality, the aim is to review the current literature to create enough evidence about the recent trends of mortality in patients with acromegaly. Moreover, this review aims to identify the possible etiology and the related risk factors. Old studies have reported that cardiovascular complications were the major etiology for death among acromegalic patients. However, recent studies showed that malignancies-induced complications might be the leading factor, while other studies reported that cardiovascular complications are still the main culprit. Nonetheless, the recently estimated risk is similar to that in the general population. Studies reported a decrease in mortality rates among patients with acromegaly within the last decades, which is probably attributable to the recent changes in the management updates, the less frequent exposure to radiotherapy and focus on the common cardiovascular disorders associated with the disease. This review also found that exposure to radiotherapy, old age, hypopituitarism, active acromegaly, and high growth hormone (GH) levels are significant predictors of mortality in acromegalic patients. In conclusion, more effort should be made to decrease GH to favorable levels based on the recent guidelines.